Cortechs.ai | Cortechs.ai accelerates strategic expansion into European market

Cortechs.ai accelerates strategic expansion into European market

Cortechs.ai grows quantitative brain imaging operations in Europe

(San Diego, CA) May 26, 2016 – Cortechs.ai, the leading medical software innovator providing trusted solutions for quantitative brain analysis, is pleased to announce the acceleration of its international expansion to the European market to address the growing demand for quantitative imaging solutions and to support its existing customer base in Europe.

Cortechs.ai’ flagship solution, NeuroQuant®, received CE mark clearance in 2014, paving the way for many European customers to use Cortechs.ai’ fully automated quantitative brain imaging solutions in clinical practice. Cortechs.ai’ quantitative imaging solutions, NeuroQuant and PETQuant™ provide neurologists, radiologists, and clinical researchers with accurate and convenient tools to quantify the volumes of specific brain structures providing evidenced-based assessments of brain atrophy which could be caused by neurological conditions such as Alzheimer’s disease, brain trauma, multiple sclerosis, epilepsy and brain development.

In conjunction with the expansion into Europe, Cortechs.ai has hired Peter Segers, MSc, to head the European team. Mr. Segers joins the company with over 18 years of market and business development experience in medical devices, with senior roles at Lightpoint Medical, Nucletron and BMEYE, as well as, Philips Medical Systems. He brings a wealth of expertise in building global enterprise relationships and has an extensive knowledge of medical imaging market. Mr. Segers is based out of Amsterdam.

“Our international expansion is a critical step in providing continuing access and support of Cortechs.ai’ proven and reliable quantitative volumetric analysis solutions,” said Guri Stark, CEO of Cortechs.ai. “NeuroQuant has experienced impressive acceptance and success in prominent clinical institutions in the US and we are excited to see the demand and growth in Europe as we expand our solutions and launch our new Multiple Sclerosis products later this summer.”

For more information about Cortechs.ai brain imaging analysis solutions, please visit Stand D40 at the 2nd Congress of the European Academy of Neurology (EAN) taking place May 28-31 in Copenhagen.

PETQuant is available for research use only.

About Cortechs.ai
Cortechs.ai develops and markets breakthrough medical device software solutions capable of automatically segmenting and quantifying brain structures, making quantitative analysis of the human brain a routine part of clinical practice. Cortechs.ai’ cutting-edge brain imaging analysis solutions provide neurologists, radiologists, and clinical researchers worldwide with a convenient and cost-effective means to quantify subcortical structures to help assess a variety of neurological conditions, such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma and brain development. Please visit cortechs.ai for further information.

###

 

Contact: Travis Foegler
Phone: +1 (619) 450-9094
Email: Tfoegler@cortechs.ai

More Resources

01/22/2026

Reflecting on a Transformative Year at Cortechs.ai

As we enter 2026, we want to take a moment to reflect on what has been a truly impactful year at Cortechs.ai.

12/18/2025

Reimbursement Essentials for Quantitative Imaging: Key Takeaways From Our Expert Webinar

Our reimbursement webinar walked through best practices for billing, coding, and securing payment for NeuroQuant and OnQ Prostate, helping inform providers.

12/15/2025

OnQ Prostate for Radiation Oncology

OnQ Prostate is at the forefront of advanced imaging to empower the delivery of true precision therapies.

12/10/2025

Reflections on RSNA 2025 and What We Learned at the Cortechs.ai Booth 

If there was one overall takeaway from RSNA 2025, it’s that clinicians are ready for tools that reduce manual work and make reporting more consistent.

12/09/2025

Dementia Imaging: Case-based PET/MRI Approach

Join us for a webinar that will unlock the latest insights in dementia imaging with Dr. Ana M. Franceschi, MD PhD.

12/09/2025

SNO 2025 Recap: Collaboration Driving Innovation in Neuro-Oncology

The 2025 Society for Neuro-Oncology meeting was more than a conference, it was a hub of collaboration and conversation among industry leaders and physicians.
Scroll to Top